3. Nouvelles strategies dans le traitement des vasculites associees aux ANCA. [New therapeutic strategies in ANCA-associated systemic vasculitis]

Details

Serval ID
serval:BIB_BF600F0819D1
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
3. Nouvelles strategies dans le traitement des vasculites associees aux ANCA. [New therapeutic strategies in ANCA-associated systemic vasculitis]
Journal
Revue Médicale Suisse
Author(s)
Ruiz  F. L., Bart  P. A.
ISSN
1660-9379 (Print)
Publication state
Published
Issued date
01/2005
Volume
1
Number
1
Pages
19-23
Notes
English Abstract
Journal Article
Review --- Old month value: Jan 5
Abstract
High-dose corticosteroids in combination with cytotoxic drugs are universally accepted as the initial treatment in ANCA-associated vasculitis. Cyclophosphamide is the most effective cytotoxic drug and is used in more severe cases. Because of short- and long-term side-effects, novel therapies have been tested. New prospects for the treatment of vasculitis include sequential chemotherapy (e.g. cyclophosphamide followed by azathioprine or cyclophosphamide followed by methotrexate) and/or novel immunosuppressive agents (e.g. mycophenolate mofetil, anti-TNF-alpha).
Keywords
Antibodies, Antineutrophil Cytoplasmic/*immunology Azathioprine/therapeutic use Humans Immunosuppressive Agents/therapeutic use Vasculitis, Hypersensitivity/*drug therapy/*immunology
Pubmed
Create date
25/01/2008 15:49
Last modification date
20/08/2019 16:33
Usage data